SASP itself is a known inducer of ferroptosis; when used in combination with vorinostat it can further promote this process by targeting SLC7A11 expression which is related to cancer cell insensitivity to HDAC inhibitors [92]. The gene discussed is SLC7A11; the disease is cancer.